The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs' cost should be covered by Medicare, Medicaid and private insurers.
American seniors still pay more for health care than their counterparts in most other wealthy countries do, despite coverage by Medicare, a new study finds.